Kamina

Quick links to important sections

Kamina

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kamina

Property Description
Active ingredient Amikacin (Amikacin sulfate)
Form Sterile injectable solution, liposomal solution (for inhalation)
Pharmacological class Semi-synthetic aminoglycoside antibiotic
Common use Treatment of serious bacterial infections
Origin Semi-synthetic (derived from Kanamycin A)

Kamina is the trade name for the essential medication Amikacin, which is classified as a semi-synthetic aminoglycoside antibiotic. This medication belongs to the broader class of anti-bacterial agents and is specifically engineered to combat susceptible bacterial pathogens, particularly those exhibiting multidrug resistance. Amikacin is categorized as an essential medication due to its efficacy against serious infections.

Classification and Composition

Amikacin is a powerful, single-entity drug derived from Kanamycin A, featuring crucial chemical alterations that allow it to bypass deactivation by many bacterial enzymes. This structural profile makes Amikacin highly effective where older aminoglycosides, such as Gentamicin, may fail due to acquired resistance, a distinction that supports its use as a reserve antibiotic.

The product is formulated primarily as a sterile, aqueous injectable solution containing Amikacin sulfate. Because Amikacin is poorly absorbed by the digestive system, it is administered via the parenteral route (intravenous or intramuscular injection) to guarantee that therapeutic levels are delivered directly into the bloodstream. Its general purpose is achieved through its bactericidal action, which kills pathogens by halting their internal protein synthesis.

Regulatory References

  1. Amikacin Sulfate - Drug Information - FDA Label
  2. National Library of Medicine
  3. Amikacin Sulfate Injection, USP - DailyMed
  4. Parenteral Route of Administration - DailyMed
  5. Amikacin Mechanism of Action - NIH StatPearls

What side effects are possible with Kamina?

Possible Side Effects and Safety Information

The safety profile of Kamina (Amikacin) is officially defined by government regulatory bodies, focusing primarily on its potential for toxicity to the kidneys and the nervous system.

Adverse Reaction Scope (Based on Regulatory Labels) Details
Key Adverse Reaction Categories Nephrotoxicity (kidney damage) and Neurotoxicity, specifically Ototoxicity (damage to the eighth cranial nerve, affecting hearing and balance).
Common Side Effects (1% to 10%) Azotemia (elevated blood urea nitrogen), increased serum creatinine, decreased renal function, and permanent hearing loss.
Serious Adverse Reactions Irreversible bilateral auditory and vestibular damage (permanent deafness), acute renal failure, neuromuscular blockade leading to acute paralysis or apnea, and Clostridium difficile-associated diarrhea (CDAD).
Time-Related Patterns Risk of toxicity increases with prolonged therapy (e.g., beyond 7–14 days). Damage to the ear's cochlea may not become apparent until after the drug has been discontinued.

Population-Specific Safety Considerations

Official labeling identifies populations at increased risk, including patients with impaired renal function and older adults, where the risk of ototoxicity and nephrotoxicity is significantly greater. The medication is associated with the risk of congenital deafness if administered during pregnancy. Increased likelihood of serious side effects is also noted in neonates/newborn infants.

Safety-Related Restrictions

Amikacin is generally restricted for use in patients with a history of hypersensitivity to other aminoglycosides due to known cross-sensitivities. The product may contain sodium metabisulfite, an excipient that is noted in official documents for its potential to cause allergic-type reactions, particularly in susceptible people such as those with asthma. Patients should be well hydrated during therapy, as dehydration may increase the risk of toxicity.

Overdose and Emergency Response

Overdose of Kamina (Amikacin) is primarily associated with severe toxicity to the kidneys and the eighth cranial nerve, as documented in official regulatory labeling. Manifestations of overdose include neurotoxicity, which can present as tinnitus, vertigo, and potentially irreversible bilateral auditory ototoxicity, leading to permanent deafness. Nephrotoxicity is defined by signs such as decreased urine output (oliguria), and physiological changes like elevated serum creatinine, indicating acute renal failure.

Overdose may lead to life-threatening outcomes, including acute muscular paralysis and apnea resulting from neuromuscular blockade. Because of these serious risks, urgent medical attention must be sought immediately if a person exhibits symptoms such as seizure, collapse, or difficulty breathing, or if a suspected overdose has occurred. Immediate emergency services (911 or equivalent) must be contacted under these conditions.

Treatment focuses on supportive management, as no specific antidote is known. Regulatory guidance specifies that the drug should be discontinued immediately if evidence of ototoxicity or nephrotoxicity is observed. Furthermore, supportive procedures like hemodialysis and mechanical respiratory assistance may be employed to manage severe systemic effects. The risk of toxicity is officially noted as being higher in patients with pre-existing impaired renal function and in the elderly.

Therapeutic Uses of Kamina

What Kamina Treats: Main Uses and Benefits

This medication is used to treat certain serious infections caused by bacteria, including infections of the blood, abdomen, lungs, skin, bones, joints, and urinary tract. Kamina is a therapeutic option reserved for serious, acute bacterial infections and is relevant for addressing symptoms related to heightened physiological activity and systemic imbalance.

The medication is commonly used to help with infections caused by multidrug-resistant Gram-negative bacteria, a scenario where standard options may not be appropriate. This targeted use is applied across domains where additional symptomatic support is needed. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as use in the Intensive Care Unit (ICU) for critically ill adults and for the management of suspected or confirmed sepsis in neonates.

“This use is commonly applied when short-term symptomatic assistance is needed for vulnerable patients during acute phases of infection.”

The medication assists with maintaining functional stability and contributes to easing the overall symptom load for the patient during severe, acute episodes.


Quick Fact: Relief for Systemic Imbalance

The medication is commonly used across conditions presenting with acute episodes that are marked by symptoms related to systemic imbalance, where supportive relief is needed to help with intense, disruptive manifestations.

Regulatory References

  1. MedlinePlus Drug Information on Amikacin

Eligibility and Restrictions for Use

Official Eligibility Rules for Kamina (Amikacin)

Official regulatory documents define who is eligible to use Kamina through a series of absolute contraindications and mandatory restrictions based on patient status.

Eligibility Scope Status as per Regulatory Label
Contraindicated Populations Must NOT be used in patients with known hypersensitivity to Amikacin, any other aminoglycoside, or sulfites [DailyMed/FDA].
Age Groups Approved for adults, adolescents, children, and neonates, with specialized regimens for pediatric patients and neonates [SmPC].
Renal Function Restricted Use: Permitted, but requires mandatory dose adjustment and close monitoring of kidney function due to the drug’s elimination route [DailyMed/FDA].
Comorbid Conditions Caution Required: Use with caution in patients with Myasthenia Gravis, Parkinsonism, pre-existing hearing or vestibular damage, or those previously treated with ototoxic/nephrotoxic agents [SmPC/FDA].
Pregnancy Avoided/Conditional: Use during pregnancy is generally avoided due to the potential for fetal harm, including the risk of congenital deafness, and is restricted to cases where no safer alternative exists [FDA/AU TGA].
Lactation Not Recommended: A decision must be made to discontinue breastfeeding or discontinue the drug due to the potential for adverse effects on the infant [NIH LactMed].

Kamina is permitted for standard use in adults and children with normal organ function. Conversely, eligibility is severely limited or prohibited for specific patient groups defined by immune status and inherent risk factors.

What should I know about interactions with other medicines?

Kamina, an injectable aminoglycoside, has officially documented interaction patterns that center on the risk of additive organ toxicity. Regulatory labeling establishes that concurrent or sequential use with other medicinal products known to be toxic to the kidneys (nephrotoxic) or the auditory nerve (ototoxic) must be avoided due to the additive risk. These agents include specific antibiotics, such as vancomycin and cisplatin, as well as potent diuretics like furosemide, which are noted to increase the risk of ototoxicity through pharmacodynamic synergism.

A formal contraindication is documented for combining Kamina with live bacterial vaccines (such as BCG or cholera vaccine), where the antibiotic decreases the vaccine’s effectiveness through a pharmacodynamic antagonism mechanism. Co-administration with neuromuscular blocking agents may also potentiate muscle weakness and respiratory effects.

Other documented interactions involve exposure modification. Certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and the agent Quinidine, are noted in regulatory information to increase the concentration of Kamina in the bloodstream, with the latter involving the P-glycoprotein transporter. A strict physical and timing rule requires that Kamina must not be physically mixed with other medications in the same container, necessitating separate administration. The risk and severity of these documented interactions are noted to be amplified in patient populations with advanced age, dehydration, or existing renal impairment.

Mechanism of Action

How Kamina Works — Mechanism of Action

Kamina (Amikacin) acts as a molecular inhibitor by physically and irreversibly binding to the bacterial 30S ribosomal subunit, specifically interacting with components of the 16S ribosomal RNA. This binding obstructs the bacteria's core process of protein synthesis. This mechanism is concentrated exclusively on prokaryotic (bacterial) ribosomes.

The drug's binding distorts the ribosomal decoding site (A-site), forcing the translational machinery to misread the genetic template and leading to the creation of toxic, non-functional proteins. The synthesis of these aberrant proteins is a physiological consequence. These proteins are inserted into the bacterial membrane, causing rapid structural collapse and ultimately triggering an irreversible bactericidal effect.

The mechanism is driven by concentration-dependent killing, where the speed of bacterial elimination is proportional to the peak drug levels achieved at the site of action. This irreversible ribosomal damage also generates a Post-Antibiotic Effect (PAE), meaning the sustained inhibition of protein synthesis persists beyond the immediate presence of high drug concentrations.

Dosage and Administration Information

Kamina (Amikacin) administration follows two distinct protocols based on the formulation being used.

Parenteral Administration

The sterile solution is delivered via the parenteral route, either as an Intramuscular (IM) injection or an Intravenous (IV) infusion. The typical dosing schedule involves a total daily dose of 15 mg/kg of body weight, which is often administered in two divided doses of 7.5 mg/kg every 12 hours. For IV use, the solution must be diluted in a compatible fluid and infused over a controlled period of 30 to 60 minutes. Therapy for this route is generally limited to a duration of 7 to 10 days. Guidelines require a dosage reduction in patients with impaired renal function, and a specific regimen, starting with a 10 mg/kg loading dose, applies to neonates.

Oral Inhalation Administration

Alternatively, the liposomal suspension is intended for Oral Inhalation and must be administered using the designated Lamira Nebulizer System. This protocol uses a fixed dose of 590 mg, administered once daily. The duration of treatment is long-term, potentially continuing for 12 months following confirmed culture conversion. If a dose of the liposomal suspension is missed, the instruction is to administer the next scheduled dose on the following day; the dose must not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kamina

This summary is designed to explain the clinical research surrounding Amikacin (Kamina) in a clear way, focusing on what has been studied and what remains uncertain. It is not medical advice and does not provide dosing, safety information, or treatment recommendations.


Evidence for Use in Serious Systemic Bacterial Infections (Injectable Amikacin)

Amikacin injection was studied for the management of serious bacterial infections, particularly those that involve Gram-negative bacteria and organisms that were not susceptible to certain older antibiotics were included in the research. The research landscape includes early clinical studies and later Randomized Controlled Trials (RCTs). These studies typically monitored outcomes related to microbiological eradication (measurements of bacterial clearance) and clinical remission (measurements of changes in infection signs).

Research on specific concentration goals is complemented by modeling studies that examine how the drug moves through the body, which contributes to the broader evidence landscape regarding concentration levels. A systematic review indicates that published evidence is limited in defining a single, clear target drug concentration in the blood that is consistently tied to the outcomes observed in the studies across all patients. This indicates that finding a single optimal regimen is not yet well-defined in the research.


Evidence for Use in Refractory Chronic Lung Disease (Inhaled Liposomal Amikacin)

Research has explored a specialized, inhaled formulation of Amikacin for adults with a chronic lung infection caused by Mycobacterium avium Complex (MAC). This research focused on patients whose infection has persisted despite prior standard therapy.

Evidence is derived from a randomized Phase 3 trial. The findings describe patterns observed in the study where adding the inhaled drug was associated with a higher percentage of patients achieving the primary endpoint of sputum culture conversion (a surrogate endpoint defined as achieving three consecutive negative monthly sputum tests) compared to standard therapy alone.


Evidence Gaps and Research Uncertainty

For the inhaled liposomal Amikacin, a major limitation is that the effectiveness measurement was based on a surrogate endpoint. This means there is limited information to establish a direct, definitive link between this microbiological change and overall long-term patient well-being, such as outcomes reflecting daily functioning or disease progression over many years. Furthermore, comparative evidence is lacking to definitively show how this formulation compares to older intravenous Amikacin regimens for the condition characterized by chronic lung manifestations. Further research is needed to collect data on patient-reported outcomes describing perceived discomfort and quality of life over time.

Key Studies & References

  1. Amikacin - StatPearls - NCBI Bookshelf - NIH (General overview of indications and dosing strategies)
  2. Single or multiple daily doses of aminoglycosides: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Kamina (FAQ)

Q: How quickly does Kamina start to work?

Official pharmacokinetic data describes the speed at which the medication is absorbed and reaches its highest levels in the bloodstream. For injectable forms, maximum concentrations are typically reached within 45 minutes to 2 hours after intramuscular administration, or immediately following intravenous infusion. This speed of reaching peak concentration is relevant to how the drug achieves its desired concentration-dependent activity.

Q: What happens if I miss a dose of Kamina?

Regulatory guidance describes that if a dose of the injectable form is missed, it is typically administered as soon as possible. If it is nearly time for the next scheduled dose, the prescribed instruction is to omit the missed dose entirely. Official sources describe the importance of not administering two doses at once.

Q: Can I stop taking Kamina if I feel better?

Official guidance describes that the full course of treatment is typically completed, even if symptoms begin to improve or go away before the course is finished. This practice is described as standard to help ensure the infection is fully treated and to potentially mitigate the risk of future infections becoming resistant to the medication.

Q: Is Kamina habit-forming or addictive?

Official regulatory documents classify this medication as an antibiotic used for serious infections. These documents do not include warnings or information regarding habit-forming potential or physical dependence. The primary focus of official warnings relates to potential physical toxicities to the ears and kidneys.

Q: Can Kamina be taken with common pain relievers like ibuprofen?

Official drug interaction information notes that co-administration of Kamina with pain relievers belonging to the NSAID class, which includes ibuprofen, may increase the potential for kidney damage. This is due to the known additive risk of nephrotoxicity (kidney toxicity) when these types of medications are used together.

Q: Are there any foods I should avoid while using Kamina?

Official labeling does not list specific foods that must be restricted while using this medication. The general guidance is that patients maintain a normal diet unless specific instructions are provided by their healthcare provider.

Q: What is the research evidence for how well Kamina works?

Research and official documents describe the drug's efficacy (how well it works) by its ability to treat specific susceptible bacteria in serious infections. Clinical studies focus on outcomes like achieving microbiological eradication (bacterial clearance) or culture conversion. These endpoints are the metrics used to establish the effectiveness described in official research summaries.

Q: How does Kamina compare to similar medicines for the same condition?

Official documentation notes that Kamina's chemical structure is noted for its ability to bypass certain bacterial deactivation enzymes. This allows it to be effective against organisms that have developed resistance to some older aminoglycosides, such as gentamicin and tobramycin.

Q: Why do doctors prescribe Kamina instead of X drug?

This medication is reserved for use in treating serious infections caused by specific susceptible bacteria. Official indications often restrict its use to situations where other, less toxic antibiotics are not effective or when the bacteria show multi-drug resistance.

Q: Can I take vitamins or supplements while on Kamina?

Official patient information describes the importance of informing a healthcare provider of all other products being used, including all vitamins, non-prescription medications, and herbal supplements. This reporting supports the necessary monitoring for potential interactions.

Q: Does Kamina interact with herbal products like St. John's Wort?

While the official label may not detail specific interactions with every herbal product, official patient information describes that a healthcare provider should be informed of all herbal supplements being taken. This is due to the potential for unrecognized interactions and supports appropriate monitoring during treatment.

Q: Is it safe to drive or operate machinery while taking Kamina?

Because this medication may cause dizziness, drowsiness, or tiredness in some patients, official documents describe the need for caution before driving or operating machinery until the effects of the drug are known.

Q: What are the common signs that Kamina is starting to work?

Official drug information suggests that a clinical response—meaning an improvement in the signs of infection—for uncomplicated infections due to susceptible organisms may be evident within 24 to 48 hours of starting treatment. Monitoring of general symptoms is typically recommended.

Q: Are there different forms of Kamina (e.g., tablet, liquid)?

The active ingredient is formulated as a sterile injectable solution, intended for intramuscular or intravenous use. It also comes as a liposomal suspension approved only for oral inhalation via a specific nebulizer system. No oral tablet or general liquid formulation is approved because the drug is poorly absorbed by the digestive system.

Q: Do I need a special diet when taking Kamina?

Official labeling generally describes that patients maintain a normal diet unless otherwise directed by their healthcare provider. Adequate hydration is a key factor described in official documents due to the drug's potential effects on the kidneys.

Q: Does the efficacy of Kamina decrease over long-term use?

Microbiology literature addresses a phenomenon called 'adaptive resistance,' where bacterial cells can temporarily decrease drug uptake during treatment. However, the greater concern noted in official documents regarding prolonged therapy is the increased risk of known toxicities, especially to the kidneys and ears.

Q: What is the half-life of Kamina?

The drug's elimination half-life is a pharmacokinetic parameter that describes how long it takes for the drug concentration in the body to drop by half. This value is used by healthcare providers to guide dosing, particularly for patients with impaired kidney function. In adults with normal renal function, the half-life is typically described as being approximately 2 to 3 hours.

Q: What happens if I accidentally take two doses of Kamina?

Signs of excessive concentrations, or overdose, are noted in official documents and may include severe effects like ringing in the ears, hearing difficulties, and dizziness. Other symptoms could include problems with passing urine or pins and needles in the hands and feet.

Q: What is the general success rate mentioned in studies for Kamina?

Clinical trial evidence defines success by specific microbiological endpoints rather than a simple percentage rate. These endpoints include achieving bacterial clearance or specific culture conversion for the infections for which the drug is indicated, which forms the basis for regulatory approval.

Q: Does Kamina interact with alcohol?

While a direct, named interaction with alcohol is not typically detailed in official labeling, maintaining adequate hydration is a factor described in official documents as potentially reducing the risk of toxicity with this medication. Caution is generally recommended by health bodies when taking antibiotics.

Q: Does Kamina cause weight gain or loss?

Official documents do not list weight change as a common standalone side effect of this medication. However, sudden weight gain or loss is noted as a possible symptom associated with serious adverse reactions, specifically decreased renal function.

Q: Is it normal to feel tired after starting Kamina?

Drowsiness and tiredness are noted in official documents as possible side effects of the medication. Patients who experience side effects that bother them are typically instructed to inform their healthcare provider.

Q: What should I do if a side effect is bothering me?

Official patient advice describes the need to inform a healthcare provider or nurse if any side effects are experienced that are bothersome or persistent. This reporting supports the appropriate care and monitoring during treatment.

Q: Does taking Kamina affect results of common lab tests?

This medication requires mandatory monitoring of lab tests, such as blood urea nitrogen (BUN) and serum creatinine, to assess kidney function during therapy. The presence of other antibiotics may also interfere with the accuracy of the drug level measurement test itself.

How should Kamina be stored and disposed of?

Kamina (amikacin sulfate) injectable solution must be stored in accordance with official regulatory requirements to ensure its stability and integrity.


Storage Requirements

  • Temperature and Protection: The unopened solution must be stored at or below 25 C (77 F). It is mandatory to protect the solution from freezing and light.
  • Child Safety: Keep this medicine out of the sight and reach of children.
  • Stability: The vial is for single use only. After dilution, the solution should be used immediately. If necessary, the prepared solution may be stored for up to 24 hours at 2 C to 8 C (refrigerated) if prepared under aseptic conditions.

Disposal Instructions

  • Unused Product: Any remaining solution in the single-use vial must be discarded.
  • Environmental Safety: Do not throw away any medicines via wastewater or household waste. Consult a pharmacist for the proper procedure for disposing of unused or expired medicine, which must comply with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kamina found in:

A-Z Index: